Gene Editing CDMOs with Clean FDA Inspection History
Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.
Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 7 NAI (no action), 5 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (10), France (4), Germany (3), Ireland (3), UNITED KINGDOM (3).
Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 2 |
RC
|
79.3 | 96.8 | 1 insp · 1 GMP | 2025-01-21 · VAI | Available | — |
| 3 |
GP
San Diego, CA
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 4 |
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
|
77.3 | 92.9 | 2 insp · 0 GMP | 2025-03-14 · NAI | — | 34 programs |